RE:RevenuesIMHO rev came in as forecasted but the loss was somewhat unexpected. As for the reasons pushing back the target date for the commercial PGX scale up (though some have speculated a hold) we do not have an official answer. Funds are on hand ($14M) to fund the AV trial, PGX install and would be able to cover the Y-BG study if it was a go.
As for revenues this year, that remains a mystery, do we continue on historical trends?
I would say that this comment from the NR is perplexing;
"We kicked off the year with the signing of a three-year renewable Supply and Distribution Agreement with leading global active ingredients provider, Symrise, which served as a major catalyst to our best ever financial performance year in the Company’s history"
We know that sales growth for the year was in the range of the "8 - 10%" and there was no contribution yet from the CRO or any surprises (in 2022 or even in prior years) from the Symrise contract renewal. The comment makes no sense to me as the Symrise contract that renews every 3 years, was not a catalyst for revenues, growth was in line with the historical trend and it took it to where it was.